TIL

Read the latest insights and research related to tumor-infiltrating lymphocyte (TIL) therapy, a form of immunotherapy that treats cancerous tumors.

TIL

Real-World Clinical Outcomes in Melanoma Patients Treated at a Single-Center Tumor Infiltrating Lymphocyte (TIL) Therapy Program Using Commercial Lifileucel

by Alex Kadhim

This real-world study demonstrates that lifileucel TIL therapy can deliver strong responses in advanced melanoma, with high response rates and encouraging survival among treated patients. However,...

TIL

Proteostasis Sustains T Cell Differentiation Potential and Tumor-Infiltrating Lymphocyte Function

by Alex Kadhim

New findings highlight proteostasis as a key driver of T cell differentiation and antitumor function, identifying protein-quality control as a critical factor in preventing T cell exhaustion. By...

TIL

Adoptive Cell Therapies Offer ‘New Hope’ for Patients With Limited Treatment Options

by C. Brooke Adams, PharmD, BCOP

The cellular therapy landscape continues to evolve beyond hematologic malignancies, now making significant progress in solid tumor treatment. Certain characteristics seen in solid tumors...

TIL

Optimizing Care for TILs, Cellular Therapy in Melanoma and Solid Tumors

by Oncology On the Go and ASTCT Talks

A panel of oncology pharmacists discusses the role oflifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors.

TIL

Deletion of Cbl-b inhibits CAR T-cell exhaustion

by Abstracts Newsletter

Scientists must take a closer look at Cbl-b if they want to improve chimeric antigen receptor (CAR) T-cell therapies for solid tumors, which are promising but currently less than optimal in terms...

Thank You to Our
Sponsor

TRENDING TOPICS AND NEWS IN HCT AND CELLULAR THERAPY

Topics to Explore

TIL